Development of phage lysins as novel therapeutics: A historical perspective

Viruses

Volumn 10, Issue 6, 2018, Pages

  Fischetti, Vincent A ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Alternative to antibiotics; Antibiotic resistance; Discovery; Endolysins; Lysins; Lytic enzymes; Phage; Therapeutic

Indexed keywords

AMIDASE; AMMONIUM SULFATE; CARBOHYDRATE; IMMUNOGLOBULIN A ANTIBODY; LYSIN; PEPTIDASE; PEPTIDOGLYCAN; PROTEIN; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; BIOLOGICAL PRODUCT; ENDOLYSIN; HYDROLASE; PROTEINASE;

ANTHRAX; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIOPHAGE; BINDING AFFINITY; CELL MEMBRANE; DEVELOPMENT; EFFICACY PARAMETERS; ENDOCARDITIS; ENZYME ACTIVITY; GENETIC MANIPULATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IMMUNOLOGY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL COMMUNITY; NONHUMAN; PHONETICS; PROGENY; PUBLICATION; SEQUENCE ANALYSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; ULTRACENTRIFUGATION; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; ENZYMOLOGY; HISTORY; ISOLATION AND PURIFICATION; PROCEDURES; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; ENDOPEPTIDASES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYDROLASES; STAPHYLOCOCCAL INFECTIONS;

EID: 85048492145     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v10060310     Document Type: Article

References (64)

1. Clokie, M.R.; Millard, A.D.; Letarov, A.V.; Heaphy, S. Phages in nature. Bacteriophage 2011, 1, 31–45.
2. Reche, I.; D’Orta, G.; Mladenov, N.; Winget, D.M.; Suttle, C.A. Deposition rates of viruses and bacteria above the atmospheric boundary layer. ISME J. 2018, 12, 1154–1162.
3. Nguyen, S.; Baker, K.; Padman, B.S.; Patwa, R.; Dunstan, R.A.; Weston, T.A.; Schlosser, K.; Bailey, B.; Lithgow, T.; Lazarou, M.; et al. Bacteriophage Transcytosis Provides a Mechanism to Cross Epithelial Cell Layers. mBio 2017, 8.
4. Delbruck, M. The Growth of Bacteriophage and Lysis of the Host. J. Gen. Physiol. 1940, 23, 643–660.
5. Abedon, S.T. Lysis from without. Bacteriophage 2011, 1, 46–49.
6. Wang, I.N.; Smith, D.L.; Young, R. Holins: The protein clocks of bacteriophage infections. Annu. Rev. Microbiol. 2000, 54, 799–825.
7. Jervis, E.J.; Haynes, C.A.; Kilburn, D.G. Surface diffusion of cellulases and their isolated binding domains on cellulose. J. Biol. Chem. 1997, 272, 24016–24023.
8. Payne, C.M.; Knott, B.C.; Mayes, H.B.; Hansson, H.; Himmel, M.E.; Sandgren, M.; Stahlberg, J.; Beckham, G.T. Fungal cellulases. Chem. Rev. 2015, 115, 1308–1448.
9. Hendrix, R.W. Bacteriophages: Evolution of the Majority. Theor. Popul. Biol. 2002, 61, 471–480.
10. Fenton, M.; Ross, P.; McAuliffe, O.; O’Mahony, J.; Coffey, A. Recombinant bacteriophage lysins as antibacterials. Bioeng. Bugs 2010, 1, 9–16.
11. Pastagia, M.; Schuch, R.; Fischetti, V.A.; Huang, D.B. Lysins: The arrival of pathogen-directed anti-infectives. J. Med. Microbiol. 2013, 62, 1506–1516.
12. Fischetti, V.A. Bacteriophage lytic enzymes: Novel anti-infectives. Trends Microbiol. 2005, 13, 491–496.
13. Oliveira, H.; Melo, L.D.; Santos, S.B.; Nobrega, F.L.; Ferreira, E.C.; Cerca, N.; Azeredo, J.; Kluskens, L.D. Molecular aspects and comparative genomics of bacteriophage endolysins. J. Virol. 2013, 87, 4558–4570.
14. Koller, T.; Nelson, D.; Nakata, M.; Kreutzer, M.; Fischetti, V.A.; Glocker, M.O.; Podbielski, A.; Kreikemeyer, B. PlyC, a novel bacteriophage lysin for compartment-dependent proteomics of group A streptococci. Proteomics 2008, 8, 140–148.
15. Twort, F.W. An investigation on the nature of ultra-microscopic viruses. Lanccet 1915, 186, 1241–1243.
16. D’Herelle, F.H. Sur un microbe invisible antagoniste des bacilles dysenteriques. C. R. Acad. Sci. 1917, 165, 373–375.
17. Clark, P.F.; Clark, A.S. A “bacteriophage” active against a hemolytic streptococcus. J. Bacteriol. 1926, 11, 89.
18. Evans, A.C. The Prevalence of Streptococcus Bacteriophage. Science 1934, 80, 40–41.
19. Twort, F.W. The transmissible bacterial lysin and its action on dead bacteria. Lancet 1925, 206, 642–644.
20. Maxted, W.R. The active agent in nascent phage lysis of streptococci. J. Gen. Microbiol. 1957, 16, 584–595.
21. Avery, O.T.; MacLeod, C.M.; McCarty, M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Inductions of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J. Exp. Med. 1944, 79, 137–158.
22. Krause, R.M. Studies on bacteriophages of hemolytic streptococci. I. Factors influencing the interaction of phage and susceptible host cell. J. Exp. Med. 1957, 106, 365–384.
23. Krause, R.M. Studies on the bacteriophages of hemolytic streptococci. II Antigens released from the streptococcal cell wall by a phage-associated lysin. J. Exp. Med. 1958, 108, 803–821.
24. Krause, R.M.; McCarty, M. Studies on the chemical structure of the streptococcal cell wall. I. The identification of a mucopeptide in the cell walls of groups A and A-variant streptococci. J. Exp. Med. 1961, 114, 127–140.
25. Krause, R.M.; McCarty, M. Studies on the chemical structure of the streptococcal cell wall. II. The composition of group C cell walls and chemical basis for serologic specificity of the carbohydrate moiety. J. Exp. Med. 1962, 115, 49–62.
26. Freimer, E.H.; Krause, R.M.; McCarty, M. Studies of L forms and protoplasts of group A streptococci, I. Isolation, growth, and bacteriologic characteristics. J. Exp. Med. 1959, 110, 853–874.
27. Ralston, D.J.; McIvor, M. Lysis-from-without of Staphylococcus aureus strains by combinations of specific phages and phage-induced lytic enzymes. J. Bacteriol. 1964, 88, 676–681.
28. Ralston, D.J.; McIvor, M. Cell-Wall Lysins of Staphylococcus aureus Strains Induced by Specific Typing Phages. J. Bacteriol. 1964, 88, 667–675.
29. Doughty, C.C.; Mann, J.A. Purification and properties of a bacteriophage-induced cell wall peptidase from Staphylococcus aureus. J. Bacteriol. 1967, 93, 1089–1095.
30. Schuytema, E.C.; Glenn, H.L.; Doughty, C.C. Relative rates of lysis of staphylococcal cell walls by lytic enzymes from various bacteriophage types. J. Bacteriol. 1969, 98, 920–923.
31. Doughty, C.C.; Hayashi, J.A. Enzymatic properties of a phage-induced lysin affecting group A streptococci. J. Bacteriol. 1962, 83, 1058–1068.
32. McGowan, S.; Buckle, A.M.; Mitchell, M.S.; Hoopes, J.T.; Gallagher, D.T.; Heselpoth, R.D.; Shen, Y.; Reboul, C.F.; Law, R.H.; Fischetti, V.A.; et al. X-ray crystal structure of the streptococcal specific phage lysin PlyC. Proc. Natl. Acad. Sci. USA 2012, 109, 12752–12757.
33. Barksdale, L.; Garmise, L.; Rivera, R. Toxinogeny in Corynebacterium diphtheriae. J. Bacteriol. 1961, 81, 527–540.
34. Zabriskie, J.B. The role of temperate bacteriophage in the production of erythrogenic toxin by group A streptococci. J. Exp. Med. 1964, 119, 761–779.
35. Fischetti, V.A.; Gotschlich, E.C.; Bernheimer, A.W. Purification and physical properties of group C streptococcal phage-associated lysin. J. Exp. Med. 1971, 133, 1105–1117.
36. Fischetti, V.A.; Jones, K.F.; Manjula, B.N.; Scott, J.R. Streptococcal M6 protein expressed in Escherichia coli. Localization, purification and comparison with streptococcal-derived M protein. J. Exp. Med. 1984, 159, 1083–1095.
37. Fischetti, V.A.; Jones, K.F.; Scott, J.R. Size variation of the M protein in group A streptococci. J. Exp. Med. 1985, 161, 1384–1401.
38. Pancholi, V.; Fischetti, V.A. Isolation and characterization of the cell-associated region of group A streptococcal M6 protein. J. Bacteriol. 1988, 170, 2618–2624.
39. Phillips, G.N.; Flicker, P.F.; Cohen, C.; Manjula, B.N.; Fischetti, V.A. Streptococcal M protein: Alpha-helical coiled-coil structure and arrangement on the cell surface. Proc. Natl. Acad. Sci. USA 1981, 78, 4689–4693.
40. Hollingshead, S.K.; Fischetti, V.A.; Scott, J.R. Complete nucleotide sequence of type 6 M protein of the Group A Streptococcus. J. Biol. Chem. 1986, 261, 1677–1686.
41. Cunningham, M.W.; Beachey, E.H. Peptic digestion of streptococcal M protein. I. Effect of digestion at suboptimal pH upon the biological and immunological properties of purified M protein extracts. Infect. Immun. 1974, 9, 244–248.
42. Beachey, E.H.; Stollerman, G.; Chiang, E.Y.; Chiang, T.M.; Seyer, J.M.; Kang, A.H. Purification and properties of M protein extracted from group A streptococci with pepsin: Covalent structure of the amino terminal region of type 24 M antigen. J. Exp. Med. 1977, 145, 1469–1483.
43. Beachey, E.H.; Gras-Masse, H.; Tarter, A.; Jolivet, M.; Audibert, F.; Chedid, L.; Seyer, J.M. Opsonic antibodies evoked by hybrid peptide copies of types 5 and 24 streptococcal M proteins synthesized in tandem. J. Exp. Med. 1986, 163, 1451–1458.
44. Jones, K.F.; Manjula, B.N.; Johnston, K.H.; Hollingshead, S.K.; Scott, J.R.; Fischetti, V.A. Location of variable and conserved epitopes among the multiple serotypes of streptococcal M protein. J. Exp. Med. 1985, 161, 623–628.
45. Hollingshead, S.K.; Fischetti, V.A.; Scott, J.R. A highly conserved region present in transcripts encoding heterologous M proteins of group A streptococcus. Infect. Immun. 1987, 55, 3237–3239.
46. Bessen, D.; Fischetti, V.A. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect. Immun. 1988, 56, 2666–2672.
47. Bessen, D.; Fischetti, V.A. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. J. Immunol. 1990, 145, 1251–1256.
48. Gotschlich, E.C.; Liu, T.Y.; Artenstein, M.S. Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J. Exp. Med. 1969, 129, 1349–1365.
49. Gotschlich, E.C.; Goldschneider, I.; Artenstein, M.S. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J. Exp. Med. 1969, 129, 1385–1395.
50. Perl, T.M. The threat of vancomycin resistance. Am. J. Med. 1999, 106, 26–37.
51. Rybak, M.J.; Hershberger, E.; Moldovan, T.; Grucz, R.G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. Antimicrob. Agents Chemother. 2000, 44, 1062–1066.
52. Nelson, D.; Loomis, L.; Fischetti, V.A. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. USA 2001, 98, 4107–4112.
53. Sheehan, M.M.; Garcia, J.L.; Lopez, R.; Garcia, P. The lytic enzyme of the pneumococcal phage Dp-1: A chimeric lysin of intergeneric origin. Mol. Microbiol. 1997, 25, 717–725.
54. Schuch, R.; Nelson, D.; Fischetti, V.A. A bacteriolytic agent that detects and kills Bacillus anthracis. Science 2002, 418, 884–889.
55. Loeffler, J.M.; Fischetti, V.A. Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains. Antimicrob. Agents Chemother. 2003, 47, 375–377.
56. Loeffler, J.M.; Djurkovic, S.; Fischetti, V.A. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect. Immun. 2003, 71, 6199–6204.
57. Schmitz, J.E.; Daniel, A.; Collin, M.; Schuch, R.; Fischetti, V.A. Rapid DNA library construction for functional genomic and metagenomic screening. Appl. Environ. Microbiol. 2008, 74, 1649–1652.
58. Croux, C.; Ronda, C.; Lopez, R.; Garcia, J.L. Interchange of functional domains switches enzyme specificity: Construction of a chimeric pneumococcal-clostridial cell wall lytic enzyme. Mol. Microbiol. 1993, 9, 1019–1025.
59. Sheehan, M.M.; Garcia, J.L.; Lopez, R.; Garcia, P. Analysis of the catalytic domain of the lysin of the lactococcal bacteriophage Tuc2009 by chimeric gene assembling. FEMS Microbiol. Lett. 1996, 140, 23–28.
60. Fernandes, S.; Proenca, D.; Cantante, C.; Silva, F.A.; Leandro, C.; Lourenco, S.; Milheirico, C.; de Lencastre, H.; Cavaco-Silva, P.; Pimentel, M.; et al. Novel Chimerical Endolysins with Broad Antimicrobial Activity Against Methicillin-Resistant Staphylococcus aureus. Microb. Drug Resist. 2012, 18, 333–343.
61. Briers, Y.; Schmelcher, M.; Loessner, M.J.; Hendrix, J.; Engelborghs, Y.; Volckaert, G.; Lavigne, R. The high-affinity peptidoglycan binding domain of Pseudomonas phage endolysin KZ144. Biochem. Biophys Res. Commun. 2009, 383, 187–191.
62. Daniel, A.; Euler, C.; Collin, M.; Chahales, P.; Gorelick, K.J.; Fischetti, V.A. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2010, 54, 1603–1612.
63. Czaplewski, L.; Bax, R.; Clokie, M.; Dawson, M.; Fairhead, H.; Fischetti, V.A.; Foster, S.; Gilmore, B.F.; Hancock, R.E.; Harper, D.; et al. Alternatives to antibiotics—A pipeline portfolio review. Lancet Infect. Dis. 2016, 16, 239–251.
64. Gilmer, D.B.; Schmitz, J.E; Euler, C.W.; and Fischetti, V.A. Novel Bacteriophage Lysin with Broad Lytic Activity Protects Against Mixed Infection by Streptococcus pyogenes and Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2013, 57, 2743–2750.